Ellis J Neufeld

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1481685/publications.pdf

Version: 2024-02-01

290 papers	12,174 citations	20817 60 h-index	32842 100 g-index
293 all docs	293 docs citations	293 times ranked	10521 citing authors

#	Article	IF	Citations
1	Prevalence of the Metabolic Syndrome in American Adolescents. Circulation, 2004, 110, 2494-2497.	1.6	935
2	Complications of Î²-thalassemia major in North America. Blood, 2004, 104, 34-39.	1.4	403
3	Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, The, 2003, 361, 1597-1602.	13.7	301
4	Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood, 2012, 119, 5989-5995.	1.4	284
5	Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood, 2006, 107, 3436-3441.	1.4	272
6	Human CCAAT displacement protein is homologous to the Drosophila homeoprotein, cut. Nature Genetics, 1992, 1, 50-55.	21.4	216
7	The frequency and management of asparaginaseâ€related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Danaâ€Farber Cancer Institute consortium protocols. British Journal of Haematology, 2011, 152, 452-459.	2.5	216
8	The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nature Genetics, 1999, 22, 305-308.	21.4	215
9	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	2.2	210
10	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 2006, 107, 2639-2642.	1.4	204
11	Phosphoinositide turnover provides a link in stimulusâ€”response coupling. Trends in Biochemical Sciences, 1985, 10, 168-171.	7.5	190
12	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2020, 382, 1219-1231.	27.0	177
13	Production of phosphoinositide-derived messengers. Cell, 1984, 37, 701-703.	28.9	172
14	Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood, 2008, 112, 4003-4008.	1.4	171
15	Urinary hepcidin in congenital chronic anemias. Pediatric Blood and Cancer, 2007, 48, 57-63.	1.5	157
16	Asparaginase-Associated Lipid Abnormalities in Children With Acute Lymphoblastic Leukemia. Blood, 1997, 89, 1886-1895.	1.4	142
17	Erythrocyte pyruvate kinase deficiency: 2015 status report. American Journal of Hematology, 2015, 90, 825-830.	4.1	140
18	Mobility, clustering, and transport of nerve growth factor in embryonal sensory cells and in a sympathetic neuronal cell line.. Proceedings of the National Academy of Sciences of the United States of America, 1980, 77, 3469-3473.	7.1	127

#	Article	IF	Citations
19	Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood, 2015, 126, 873-879.	1.4	124
20	Transcriptional Repression of the Cystic Fibrosis Transmembrane Conductance Regulator Gene, Mediated by CCAAT Displacement Protein/cut Homolog, Is Associated with Histone Deacetylation. Journal of Biological Chemistry, 1999, 274, 7803-7815.	3.4	122
21	Coagulation abnormalities in patients with single-ventricle physiology precede the Fontan procedure. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 459-465.	0.8	121
22	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 2018, 131, 2183-2192.	1.4	121
23	Systematic molecular genetic analysis of congenital sideroblastic anemia: Evidence for genetic heterogeneity and identification of novel mutations. Pediatric Blood and Cancer, 2010, 54, 273-278.	1.5	115
24	Repressor Activity of CCAAT Displacement Protein in HL-60 Myeloid Leukemia Cells. Journal of Biological Chemistry, 1995, 270, 12745-12750.	3.4	110
25	Sequence-specific DNA binding of individual cut repeats of the human CCAAT displacement/cut homeodomain protein.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7757-7761.	7.1	109
26	Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. British Journal of Haematology, 2011, 153, 121-128.	2.5	108
27	CDP/cut is the DNA-binding subunit of histone gene transcription factor HiNF-D: a mechanism for gene regulation at the G1/S phase cell cycle transition point independent of transcription factor E2F.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11516-11521.	7.1	108
28	Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood, 2012, 120, 748-760.	1.4	107
29	Prospective longitudinal study of coagulation profiles in children with hypoplastic left heart syndrome from stage I through Fontan completion. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 934-941.	0.8	106
30	Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. Journal of Pediatrics, 1998, 133, 275-278.	1.8	101
31	X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation. Blood, 2007, 109, 3297-3299.	1.4	100
32	Genetic Ablation of the CDP/Cux Protein C Terminus Results in Hair Cycle Defects and Reduced Male Fertility. Molecular and Cellular Biology, 2002, 22, 1424-1437.	2.3	98
33	Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 852-860.	2.0	98
34	Transfusion complications in thalassemia patients: a report from the <scp>C</scp>enters for <scp>D</scp>isease <scp>C</scp>ontrol and <scp>P</scp>revention (CME). Transfusion, 2014, 54, 972-981.	1.6	97
35	Lymphoid apoptosis and myeloid hyperplasia in CCAAT displacement protein mutant mice. Blood, 2001, 98, 3658-3667.	1.4	96
36	Induced Pluripotent Stem Cells with a Mitochondrial DNA Deletion. Stem Cells, 2013, 31, 1287-1297.	3.2	92

#	Article	IF	Citations
37	Localization of the Gene for Thiamine-Responsive Megaloblastic Anemia Syndrome, on the Long Arm of Chromosome 1, by Homozygosity Mapping. American Journal of Human Genetics, 1997, 61, 1335-1341.	6.2	90
38	Prevalence of fractures among the Thalassemia syndromes in North America. Bone, 2006, 38, 571-575.	2.9	90
39	Hormonal Contraception and Thrombotic Risk: A Multidisciplinary Approach. Pediatrics, 2011, 127, 347-357.	2.1	90
40	Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood, 2013, 121, 4457-4462.	1.4	87
41	High affinity esterification of eicosanoid precursor fatty acids by platelets.. Journal of Clinical Investigation, 1983, 72, 214-220.	8.2	86
42	Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA - Journal of the American Medical Association, 2021, 325, 2500.	7.4	83
43	Coagulation Abnormalities in Pediatric and Adult Patients After Sclerotherapy or Embolization of Vascular Anomalies. American Journal of Roentgenology, 2001, 177, 1359-1363.	2.2	82
44	Validity, Reliability, and Responsiveness of a New Measure of Health-Related Quality of Life in Children with Immune Thrombocytopenic Purpura: The Kidsâ€™ ITP Tools. Journal of Pediatrics, 2007, 150, 510-515.e1.	1.8	82
45	Thiamine-Responsive Megaloblastic Anemia: Identification of Novel Compound Heterozygotes and Mutation Update. Journal of Pediatrics, 2009, 155, 888-892.e1.	1.8	82
46	Thiamine-Responsive Megaloblastic Anemia Syndrome: A Disorder of High-Affinity Thiamine Transport. Blood Cells, Molecules, and Diseases, 2001, 27, 135-138.	1.4	81
47	Renal dysfunction in patients with thalassaemia. British Journal of Haematology, 2011, 153, 111-117.	2.5	81
48	Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood, 2012, 119, 2746-2753.	1.4	78
49	Cux/CDP Homeoprotein Is a Component of NF-Î¼NR and Represses the Immunoglobulin Heavy Chain Intronic Enhancer by Antagonizing the Bright Transcription Activator. Molecular and Cellular Biology, 1999, 19, 284-295.	2.3	76
50	Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood, 2009, 114, 4009-4013.	1.4	75
51	Passive Cigarette Smoking and Reduced HDL Cholesterol Levels in Children With High-Risk Lipid Profiles. Circulation, 1997, 96, 1403-1407.	1.6	75
52	Defective high-affinity thiamine transporter leads to cell death in thiamine-responsive megaloblastic anemia syndrome fibroblasts. Journal of Clinical Investigation, 1999, 103, 723-729.	8.2	75
53	Treatment with Rituximab in Benign and Malignant Hematologic Disorders in Children. Journal of Pediatrics, 2007, 150, 338-344.e1.	1.8	70
54	Inflammation and oxidant-stress in Â-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica, 2008, 93, 817-825.	3.5	67

#	Article	IF	Citations
55	Uptake and subcellular distribution of [3H]arachidonic acid in murine fibrosarcoma cells measured by electron microscope autoradiography.. Journal of Cell Biology, 1985, 101, 573-581.	5.2	65
56	Does iron overload really matter in stem cell transplantation?. American Journal of Hematology, 2012, 87, 569-572.	4.1	65
57	Guidelines for the Standard Monitoring of Patients With Thalassemia. Journal of Pediatric Hematology/Oncology, 2015, 37, e162-e169.	0.6	65
58	Clinical Effects and Safety of Rituximab for Treatment of Refractory Pediatric Autoimmune Diseases. Journal of Pediatrics, 2007, 150, 376-382.	1.8	64
59	Quality of life in thalassemia: A comparison of SFâ€36 results from the thalassemia longitudinal cohort to reported literature and the US norms. American Journal of Hematology, 2011, 86, 92-95.	4.1	63
60	Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology, 2011, 86, 433-436.	4.1	63
61	PROSPECTIVE REEVALUATION OF THE ASSOCIATION BETWEEN THROMBOTIC DIATHESIS AND LEGG-PERTHES DISEASE. Journal of Bone and Joint Surgery - Series A, 2002, 84, 1613-1618.	3.0	62
62	Mechanism of thiamine uptake by human colonocytes: studies with cultured colonic epithelial cell line NCM460. American Journal of Physiology - Renal Physiology, 2001, 281, G144-G150.	3.4	61
63	Deletion of SLC19A2, the High Affinity Thiamine Transporter, Causes Selective Inner Hair Cell Loss and an Auditory Neuropathy Phenotype. JARO - Journal of the Association for Research in Otolaryngology, 2006, 7, 211-217.	1.8	61
64	Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter. Clinical Immunology, 2009, 133, 287-294.	3.2	61
65	Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA(Arg303X/Cys338Tyr). Blood, 2004, 103, 2401-2403.	1.4	60
66	Cardiopulmonary Bypass, Myocardial Management, and Support Techniques. Journal of Thoracic and Cardiovascular Surgery, 1994, 107, 1183-1192.	0.8	57
67	Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood, 2003, 102, 3556-3561.	1.4	57
68	CCAAT Displacement Protein (CDP/cut) Recognizes a Silencer Element Within the Lactoferrin Gene Promoter. Blood, 1997, 90, 2784-2795.	1.4	56
69	Female monozygotic twins discordant for hemophilia A due to nonrandom Xâ€chromosome inactivation. American Journal of Hematology, 2008, 83, 778-780.	4.1	56
70	HEMOPHILIA. Hematology/Oncology Clinics of North America, 1998, 12, 1315-1344.	2.2	55
71	Successful Use of Bivalirudin for Cardiac Transplantation in a Child With Heparin-induced Thrombocytopenia. Journal of Heart and Lung Transplantation, 2006, 25, 1376-1379.	0.6	55
72	Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood, 2011, 118, 3794-3802.	1.4	55

#	Article	IF	Citations
73	Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. Magnetic Resonance Imaging, 2015, 33, 761-767.	1.8	54
74	Corticosteroids for acute chest syndrome in children with sickle cell disease: Variation in use and association with length of stay and readmission. American Journal of Hematology, 2010, 85, 24-28.	4.1	53
75	Hypoxia enhances stimulus-dependent induction of E-selectin on aortic endothelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7075-7080.	7.1	52
76	Transition from pediatric to adult care for sickle cell disease: Results of a survey of pediatric providers. American Journal of Hematology, 2011, 86, 512-515.	4.1	52
77	One year followâ€up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatric Blood and Cancer, 2009, 52, 259-262.	1.5	51
78	Update on Iron Chelators in Thalassemia. Hematology American Society of Hematology Education Program, 2010, 2010, 451-455.	2.5	50
79	Safety update on the use of recombinant activated factor VII in approved indications. Blood Reviews, 2015, 29, S34-S41.	5.7	50
80	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	2.3	50
81	Homeoproteins CDP and SATB1 Interact: Potential for Tissue-Specific Regulation. Molecular and Cellular Biology, 1999, 19, 4918-4926.	2.3	49
82	Relationship among chelator adherence, change in chelators, and quality of life in Thalassemia. Quality of Life Research, 2014, 23, 2277-2288.	3.1	49
83	Clinical outcomes in a cohort of patients with heparinâ€induced thrombocytopenia. American Journal of Hematology, 2017, 92, 730-738.	4.1	49
84	Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia, 2006, 12, 218-222.	2.1	48
85	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood, 2012, 119, 3263-3268.	1.4	48
86	Safety and efficacy of pegylated interferon Â-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica, 2008, 93, 1247-1251.	3.5	47
87	Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Annals of Hematology, 2010, 89, 95-103.	1.8	47
88	Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia. Value in Health, 2012, 15, 916-925.	0.3	47
89	Thirtyâ€day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: Risk factors and hospital variation. Pediatric Blood and Cancer, 2012, 58, 61-65.	1.5	47
90	Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 38.	3.3	47

#	Article	IF	Citations
91	Pediatric Heparin-Induced Thrombocytopenia: Prevalence, Thrombotic Risk, and Application of the 4Ts Scoring System. Journal of Pediatrics, 2015, 166, 144-150.e1.	1.8	47
92	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	3.5	46
93	Hair Defects and Pup Loss in Mice with Targeted Deletion of the First Cut Repeat Domain of theCux/CDPHomeoprotein Gene. Developmental Biology, 1998, 200, 69-81.	2.0	44
94	Rituximab for treatment of inhibitors in haemophilia A. Thrombosis and Haemostasis, 2014, 112, 445-458.	3.4	43
95	Symptoms of depression and anxiety in patients with thalassemia: Prevalence and correlates in the thalassemia longitudinal cohort. American Journal of Hematology, 2010, 85, 802-805.	4.1	42
96	The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. Journal of Thrombosis and Haemostasis, 2011, 9, 2229-2234.	3.8	42
97	Practical implications of liver and heart iron load assessment by T2*â€MRI in children and adults with transfusionâ€dependent anemias. American Journal of Hematology, 2008, 83, 781-783.	4.1	41
98	Characterization of a Murine High-Affinity Thiamine Transporter, Slc19a2. Molecular Genetics and Metabolism, 2001, 74, 273-280.	1.1	40
99	Evaluation of the Coagulation System in Children with Two-Ventricle Congenital Heart Disease. Annals of Thoracic Surgery, 2007, 83, 1797-1803.	1.3	40
100	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica, 2013, 98, 1359-1367.	3.5	40
101	Inadequate Dietary Intake in Patients with Thalassemia. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 980-990.	0.8	39
102	A novel mutation in the SLC19A2 gene in a Tunisian family with thiamine-responsive megaloblastic anaemia, diabetes and deafness syndrome. British Journal of Haematology, 2001, 113, 508-513.	2.5	38
103	Regional variation and cost implications of prescribed extended halfâ€life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia, 2019, 25, 668-675.	2.1	38
104	Blockade of selectin-mediated leukocyte adhesion improves postischemic function in lamb hearts. Annals of Thoracic Surgery, 1996, 62, 1295-1300.	1.3	37
105	The Incidence and Implications of Anti-Heparin-Platelet Factor 4 Antibody Formation in a Pediatric Cardiac Surgical Population. Anesthesia and Analgesia, 2008, 107, 371-378.	2.2	37
106	A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica, 2011, 96, 521-525.	3.5	37
107	Secondâ€line treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. American Journal of Hematology, 2019, 94, 741-750.	4.1	37
108	CASP, a novel, highly conserved alternative-splicing product of the CDP/cut/cux gene, lacks cut-repeat and homeo DNA-binding domains, and interacts with full-length CDP in vitro. Gene, 1997, 197, 73-81.	2.2	36

#	Article	IF	Citations
109	Validation and reliability of a diseaseâ€specific quality of life measure (the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 747 Td (<sc> Haematology, 2014, 164, 431-437.	2.5	36
110	Recognizing the need for personalization of haemophilia patientâ€reported outcomes in the prophylaxis era. Haemophilia, 2016, 22, 825-832.	2.1	36
111	P-selectin expression in myocardium of children undergoing cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 1995, 110, 924-933.	0.8	33
112	Induction of Interleukin-8 Messenger RNA in Heart and Skeletal Muscle During Pediatric Cardiopulmonary Bypass. Circulation, 1995, 92, 315-321.	1.6	33
113	R2 and R2* are equally effective in evaluating chronic response to iron chelation. American Journal of Hematology, 2014, 89, 505-508.	4.1	32
114	Direct measurement of LDL-C in children: performance of two surfactant-based methods in a general pediatric population. Clinical Biochemistry, 2000, 33, 89-95.	1.9	31
115	Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatric Blood and Cancer, 2015, 62, 214-218.	1.5	31
116	Hemoglobin Jamaica Plain â€" A Sickling Hemoglobin with Reduced Oxygen Affinity. New England Journal of Medicine, 2004, 351, 1532-1538.	27.0	30
117	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. American Journal of Hematology, 2018, 93, 882-888.	4.1	30
118	Severe haemophilia A in a female resulting from two de novo factor VIII mutations. British Journal of Haematology, 1995, 90, 906-909.	2.5	29
119	Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatric Blood and Cancer, 2012, 58, 221-225.	1.5	29
120	Relationship between Chronic Transfusion Therapy and Body Composition in Subjects with Thalassemia. Journal of Pediatrics, 2010, 157, 641-647.e2.	1.8	28
121	Pain as an emergent issue in thalassemia. American Journal of Hematology, 2010, 85, 367-370.	4.1	28
122	Beliefs about chelation among thalassemia patients. Health and Quality of Life Outcomes, 2012, 10, 148.	2.4	28
123	Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplantation, 2013, 48, 146-147.	2.4	27
124	Risk factors for thromboembolism in teens: when should I test?. Current Opinion in Pediatrics, 2002, 14, 370-378.	2.0	26
125	Immunogenicity, efficacy and safety of Nuwiq^{Â®} (humanâ€cl rh<scp>FVIII</scp>) in previously untreated patients with severe haemophilia Aâ€"Interim results from the NuProtect Study. Haemophilia, 2018, 24, 211-220.	2.1	26
126	Myocardial immediate early gene activation after cardiopulmonary bypass with cardiac ischemia-reperfusion. Annals of Thoracic Surgery, 2002, 73, 156-162.	1.3	25

#	Article	IF	Citations
127	Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. American Journal of Hematology, 2013, 88, 771-773.	4.1	25
128	Hemoglobin Hâ€constant spring in North America: An alpha thalassemia with frequent complications. American Journal of Hematology, 2009, 84, 759-761.	4.1	24
129	CSF 5-Methyltetrahydrofolate Serial Monitoring to Guide Treatment of Congenital Folate Malabsorption Due to Proton-Coupled Folate Transporter (PCFT) Deficiency. JIMD Reports, 2015, 24, 91-96.	1.5	24
130	Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial. Biology of Blood and Marrow Transplantation, 2018, 24, 1216-1222.	2.0	23
131	Sequence-specific binding of HMG-I(Y) to the proximal promoter of the gp91-phox gene. Biochemical and Biophysical Research Communications, 1992, 187, 563-569.	2.1	22
132	Male infertility and thiamine-dependent erythroid hypoplasia in mice lacking thiamine transporter Slc19a2. Molecular Genetics and Metabolism, 2003, 80, 234-241.	1.1	22
133	Response to mercaptopurine for refractory autoimmune cytopenias in children. Pediatric Blood and Cancer, 2009, 52, 80-84.	1.5	22
134	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British Journal of Haematology, 2015, 169, 887-898.	2.5	22
135	Refined mapping of the gene for thiamine-responsive megaloblastic anemia syndrome and evidence for genetic homogeneity. Human Genetics, 1998, 103, 455-461.	3.8	21
136	Impact of Acute Bleeding on Daily Activities of Patients with Congenital Hemophilia with Inhibitors and Their Caregivers and Families: Observations from the Dosing Observational Study in Hemophilia (DOSE). Value in Health, 2014, 17, 744-748.	0.3	20
137	The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood, 2021, 138, 1677-1690.	1.4	20
138	Symptoms of Anxiety and Depression Among Teens and Adults in the Thalassemia Longitudinal Cohort Study.. Blood, 2009, 114, 555-555.	1.4	20
139	MRI guided iron assessment and oral chelator use improve iron status in thalassemia major patients. American Journal of Hematology, 2014, 89, 684-688.	4.1	19
140	A mutant fibroblast cell line defective in glycoprotein synthesis due to a deficiency of glucosamine phosphate acetyltransferase. Archives of Biochemistry and Biophysics, 1978, 188, 323-327.	3.0	18
141	Sports Participation in Children and Adolescents with Immune Thrombocytopenia (ITP). Pediatric Blood and Cancer, 2015, 62, 2223-2225.	1.5	18
142	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	2.3	18
143	Inflammatory Bowel Disease Associated With Immune Thrombocytopenic Purpura in Children. Journal of Pediatric Gastroenterology and Nutrition, 2001, 33, 582-587.	1.8	17
144	Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatric Blood and Cancer, 2012, 58, 216-220.	1.5	17

#	Article	IF	Citations
145	Transition considerations for extended halfâ€life factor products. Haemophilia, 2015, 21, 285-288.	2.1	17
146	Recombinant porcine factor <scp>VIII</scp> for highâ€risk surgery in paediatric congenital haemophilia A with highâ€titre inhibitor. Haemophilia, 2017, 23, e93-e98.	2.1	17
147	Comorbidities and complications in adults with pyruvate kinase deficiency. European Journal of Haematology, 2021, 106, 484-492.	2.2	17
148	Risk of post-procedural bleeding in children on intravenous fish oil. American Journal of Surgery, 2017, 214, 733-737.	1.8	16
149	Trends in anti-D immune globulin for childhood immune thrombocytopenia: Usage, response rates, and adverse effects. American Journal of Hematology, 2012, 87, 315-317.	4.1	15
150	Bioengineering hemophilia Aâ€“specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. Blood Advances, 2019, 3, 4166-4176.	5.2	15
151	UPDATE ON GENETIC RISK FACTORS FOR THROMBOSIS AND ATHEROSCLEROTIC VASCULAR DISEASE. Hematology/Oncology Clinics of North America, 1998, 12, 1193-1209.	2.2	14
152	Exposure and safety of higher doses of recombinant factor VIIa â‰¥250â€ƒÎ¼gâ€ƒkgâ^'1 in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008). Haemophilia, 2011, 17, 650-656.	2.1	14
153	Safety of recombinant activated factor VII (<scp>rFVII</scp>a) in patients with congenital haemophilia with inhibitors: overall <scp>rFVII</scp>a exposure and intervals following high (>240ÂÎ¼gÂkg^{â^'1}) <scp>rFVII</scp>a doses across clinical trials and registries. Haemophilia, 2014, 20, e23-31.	2.1	14
154	Increasing observation rates in lowâ€risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP^{Â®}). Pediatric Blood and Cancer, 2017, 64, e26303.	1.5	14
155	Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thrombosis and Haemostasis, 2021, 121, 1400-1408.	3.4	14
156	Prevalence of factor V Leiden in a population of patients with congenital heart disease. Canadian Journal of Anaesthesia, 1998, 45, 1176-1180.	1.6	13
157	Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 607-614.	2.3	13
158	Directâ€toâ€consumer advertising for bleeding disorders: a content analysis and expert evaluation of advertising claims. Journal of Thrombosis and Haemostasis, 2008, 6, 1680-1684.	3.8	12
159	X-Linked Gray Platelet Syndrome Due to a GATA1 Arg216Gln Mutation.. Blood, 2005, 106, 5-5.	1.4	12
160	Preservation of arachidonoyl phospholipids during tissue processing for electron microscopic autoradiography.. Journal of Histochemistry and Cytochemistry, 1985, 33, 799-802.	2.5	11
161	Extracorporeal membrane oxygenation as a bridge to cardiac transplantation in a patient with cardiomyopathy and hemophilia A. Intensive Care Medicine, 2003, 29, 985-988.	8.2	11
162	Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices. Haemophilia, 2017, 23, 821-831.	2.1	11

#	Article	IF	Citations
163	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 163-163.	1.4	11
164	Induction of Aquaporin-1 mRNA following Cardiopulmonary Bypass and Reperfusion. Molecular Medicine, 1997, 3, 600-609.	4.4	10
165	Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients. JAMA Pediatrics, 1998, 152, 787-91.	3.0	10
166	Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. Pediatric Blood and Cancer, 2009, 52, 865-867.	1.5	10
167	Education and employment status of children and adults with thalassemia in North America. Pediatric Blood and Cancer, 2010, 55, 678-683.	1.5	10
168	Novel dominant Î²â€thalassemia: Hb Bostonâ€Kuwait [Codon 139/140(+T)]. Pediatric Blood and Cancer, 2013, 60, E131-4.	1.5	10
169	Safety and pharmacokinetics of the oral iron chelator SPâ€420 in Î²â€thalassemia. American Journal of Hematology, 2017, 92, 1356-1361.	4.1	10
170	Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics, 2018, 21, 762-769.	2.1	10
171	Pyruvate kinase deficiency in children. Pediatric Blood and Cancer, 2021, 68, e29148.	1.5	10
172	Screening and counseling for thalassemia. Blood, 2006, 107, 1735-1737.	1.4	9
173	Primary Care Cliniciansâ€™ Knowledge and Confidence About Newborn Screening for Sickle Cell Disease: Randomized Assessment of Educational Strategies. Journal of the National Medical Association, 2010, 102, 676-683.	0.8	9
174	Infantile Myofibroma or Lymphatic Malformation. Journal of Craniofacial Surgery, 2010, 21, 422-426.	0.7	9
175	Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: The experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004â€“2008). Pediatric Blood and Cancer, 2013, 60, 1178-1183.	1.5	9
176	The use of erythropoietinâ€stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience. European Journal of Haematology, 2014, 93, 161-164.	2.2	9
177	Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial). Blood, 2013, 122, 543-543.	1.4	9
178	ARMS test for diagnosis of factor VLeiden mutation, a common cause of inherited thrombotic tendency. , 1996, 10, 414-417.		8
179	Nonfasting Low-Density Lipoprotein Testing: Utility for Cholesterol Screening in Pediatric Primary Care. Clinical Pediatrics, 2007, 46, 441-445.	0.8	8
180	Observational Cohort Study of Pediatric Inpatients With Central Venous Catheters at â€œIntermediate Riskâ€•of Thrombosis and Eligible for Anticoagulant Prophylaxis. Journal of Pediatric Oncology Nursing, 2010, 27, 325-329.	1.5	8

#	Article	IF	Citations
181	Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE). Haemophilia, 2013, 19, 524-532.	2.1	8
182	A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 149-157.	0.9	8
183	Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. Pediatric Blood and Cancer, 2016, 63, 1822-1828.	1.5	8
184	Liver MRI Is Better Than Biopsy For Assessing Total Body Iron Balance: Validation By Simulation. Blood, 2013, 122, 958-958.	1.4	8
185	Increased leucocyte apoptosis in transfused Î²â€thalassaemia patients. British Journal of Haematology, 2013, 160, 399-403.	2.5	7
186	Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III von Willebrand disease (VWD). Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1006-1008.	3.8	7
187	Recombinant activated factor <scp>VII</scp> in approved indications: Update on safety. Haemophilia, 2018, 24, e275-e277.	2.1	7
188	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. Blood, 2020, 136, 8-9.	1.4	7
189	Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 249-249.	1.4	7
190	A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children. Blood, 2019, 134, 2369-2369.	1.4	7
191	Chronic Disseminated Intravascular Coagulation and Childhood-Onset Skin Necrosis Resulting From Homozygosity for a Protein C Gla Domain Mutation, Arg15Trp. Journal of Pediatric Hematology/Oncology, 2002, 24, 685-688.	0.6	6
192	Targeted ITP strategies: Do they elucidate the biology of ITP and related disorders?. Pediatric Blood and Cancer, 2006, 47, 706-709.	1.5	6
193	To Treat or Not To Treatâ€"From Guidelines to Individualized Patient Management. Seminars in Hematology, 2013, 50, S12-S17.	3.4	6
194	Center-Based Quality Initiative Targets Youth Preparedness for Medical Independence:HEMO-Milestones Toolin a Comprehensive Hemophilia Clinic Setting. Pediatric Blood and Cancer, 2016, 63, 499-503.	1.5	6
195	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood, 2015, 126, 73-73.	1.4	6
196	CCAAT Displacement Protein (CDP/cut) Recognizes a Silencer Element Within the Lactoferrin Gene Promoter. Blood, 1997, 90, 2784-2795.	1.4	6
197	Tracking the impact of the National Institutes of Health Clinical and Translational Science Awards on child health research: developing and evaluating a measurement strategy. Pediatric Research, 2012, 71, 619-624.	2.3	5
198	Human T Cell Lymphotropic Virus Type 1 Infection Among U.S. Thalassemia Patients. AIDS Research and Human Retroviruses, 2013, 29, 1006-1009.	1.1	5

#	Article	IF	Citations
199	Limited sampling strategies for accurate determination of extended halfâ€life factor VIII pharmacokinetics in severe haemophilia A patients. Haemophilia, 2021, 27, 408-416.	2.1	5
200	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. Blood, 2009, 114, 4056-4056.	1.4	5
201	Inherited dyslipidemias in childhood. Current Opinion in Pediatrics, 1993, 5, 707-711.	2.0	4
202	Remission from transfusionâ€dependence in a patient with congenital dyserythropoietic anemia (CDA) and increased intensity of iron chelation. Pediatric Blood and Cancer, 2009, 53, 1167-1168.	1.5	4
203	Future research in ITP: an ICIS consensus. Annals of Hematology, 2010, 89, 19-23.	1.8	4
204	Oral chelation: Should it be used with young children?. Pediatric Blood and Cancer, 2010, 55, 603-605.	1.5	4
205	Ringed sideroblasts in Î²â€thalassemia. Pediatric Blood and Cancer, 2017, 64, e26324.	1.5	4
206	Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP). Blood, 2010, 116, 72-72.	1.4	4
207	An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres. British Journal of Haematology, 2022, 196, 380-389.	2.5	4
208	Neufeld Replies. Gerontologist, The, 1991, 31, 417-417.	3.9	3
209	Quantitative Assessment of Drug Treatment Side Effects in Children with Idiopathic Thrombocytopenic Purpura (ITP).. Blood, 2004, 104, 3030-3030.	1.4	3
210	Relationship of Transfusion and Iron-Related Complications to Cost of Care in Thalassemia.. Blood, 2005, 106, 2240-2240.	1.4	3
211	Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study.. Blood, 2009, 114, 2016-2016.	1.4	3
212	Strategies to Improve Iron Chelation In Thalassemia Patients Poorly Responsive to Deferasirox:. Blood, 2010, 116, 4279-4279.	1.4	3
213	Preface to Cooley's Anemia: Ninth Symposium. Annals of the New York Academy of Sciences, 2010, 1202, ix-x.	3.8	2
214	Human T-cell lymphotropic virus type 1 infection among U.S. Thalassemia patients. Retrovirology, 2014, 11, .	2.0	2
215	Author's response: â€˜Transition considerations for extended half-life factor productsâ€™. Haemophilia, 2015, 21, e454-e455.	2.1	2
216	Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centreâ€based pharmacy hit the mark?. Haemophilia, 2015, 21, 190-195.	2.1	2

#	Article	IF	Citations
217	Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open, 2021, 11, e044885.	1.9	2
218	Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study. Blood, 2019, 134, 903-903.	1.4	2
219	Phamacokinetics (PK) Substudy of Rituximab in a Prospective Clinical Trial for Pediatric Chronic Immune Thrombocytopenic Purpura (cITP).. Blood, 2005, 106, 1243-1243.	1.4	2
220	Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in Î²-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.. Blood, 2005, 106, 3598-3598.	1.4	2
221	Bleeding Manifestations and Management of Children with Persistent and Chronic Immune Thrombocytopenia (ITP): Data From the Intercontinental Cooperative ITP Study Group.. Blood, 2009, 114, 1315-1315.	1.4	2
222	Phase II Trial of Rituximab in the Treatment of Inhibitors in Congenital Hemophilia A: Results of the RICH Study. Blood, 2011, 118, 27-27.	1.4	2
223	Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. Blood, 2012, 120, 1023-1023.	1.4	2
224	Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP). Blood, 2017, 130, 752-752.	1.4	2
225	Starting out right: Kozak sequences and clots. Blood, 2002, 100, 1933-1933.	1.4	1
226	Risks Factors And Mortality Associated With Doppler-Defined-Pulmonary Hypertension In Thalassemia Major: A Report From The Thalassemia Clinical Research Network Longitudinal Cohort Study. , 2011, , .		1
227	Skin Testing, Graded Challenge and Desensitization to Von Willebrand Factor (vWF) Products in Type III Von Willebrand Disease (VWD). Journal of Allergy and Clinical Immunology, 2015, 135, AB121.	2.9	1
228	Refractory autoimmune disease: an overview of when first-line therapy is not enough. Seminars in Hematology, 2016, 53, S35-S38.	3.4	1
229	Health-Related Quality of Life (HRQL) in Children with Severe, Chronic Immune Thrombocytopenia (cITP) Treated with Rituximab.. Blood, 2005, 106, 5575-5575.	1.4	1
230	Compliance with Immunizations in Splenectomized Individuals: A Study of the Splenectomized Hereditary Spherocytosis Population. Blood, 2008, 112, 1316-1316.	1.4	1
231	The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols.. Blood, 2009, 114, 3073-3073.	1.4	1
232	Safety of Exposure to Recombinant Activated FVII (rFVIIa) Doses In Patients with Hemophilia and Inhibitors (CHwI) to Factors VIII or IX.. Blood, 2010, 116, 3675-3675.	1.4	1
233	Transfusion Complications in Thalassemia: A Report From the Centers for Disease Control and Prevention (CDC). Blood, 2011, 118, 340-340.	1.4	1
234	MRI-Guided Iron Assessment and Oral Chelator Use Improve Iron Status In Thalassemia Major Patients: a Six-Year Single Center Retrospective Cohort Study. Blood, 2013, 122, 563-563.	1.4	1

#	Article	IF	Citations
235	Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates. Blood, 2014, 124, 2818-2818.	1.4	1
236	Hemophilia Joint Health Score Poorly Predicts the Need for Musculoskeletal Referrals in Routine Clinical Practice. Blood, 2016, 128, 3784-3784.	1.4	1
237	Role of Defective High-Affinity Thiamine Transporter slc19a2 in Marrow from a Mouse Model of Thiamine-Responsive Anemia Syndrome: Evidence for Defective Deoxyribose and Heme Synthesis.. Blood, 2005, 106, 516-516.	1.4	1
238	The Impact of the Child with Thalassemia On the Family: Parental Assessment by Child Health Questionnaire.. Blood, 2009, 114, 1371-1371.	1.4	1
239	Renal Dysfunction in Thalassemia.. Blood, 2009, 114, 2008-2008.	1.4	1
240	Changes In Health Status and Quality of Life In Adults with Thalassemia: Year 1 Report of the Thalassemia Longitudinal Cohort Study.. Blood, 2010, 116, 1533-1533.	1.4	1
241	Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.. Blood, 2012, 120, 2122-2122.	1.4	1
242	Coagulopathy and Vascular Malformations. , 2013, , 637-644.		1
243	The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status. Blood, 2015, 126, 2136-2136.	1.4	1
244	Iron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD). Blood, 2016, 128, 2430-2430.	1.4	1
245	Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome. Blood, 2019, 134, 1114-1114.	1.4	1
246	Hypoxia enhances inflammatory regulation of E-selectin through a cAMP-dependent pathway. Journal of the American College of Cardiology, 1996, 27, 411.	2.8	0
247	3714 SOLITARY COLONIC ULCER ASSOCIATED WITH COAGULATION FACTOR DEFICIENCY.. Gastrointestinal Endoscopy, 2000, 51, AB134.	1.0	0
248	Time course of early induction of intracellular adhesion molecule-1 messenger RNA during reperfusion, following cardiopulmonary bypass with hypothermic circulatory arrest in lambs. Pediatric Critical Care Medicine, 2003, 4, 83-88.	0.5	0
249	Myocardial iron measurements by MRI: getting to the heart of the matter. Blood, 2004, 103, 1571-1571.	1.4	0
250	Sickle severity selectors strike out. Blood, 2008, 111, 479-479.	1.4	0
251	Recognition and Management of Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia in the Emergency Department. Clinical Pediatric Emergency Medicine, 2011, 12, 245-252.	0.4	0
252	Unrelated Donor Marrow (BMT) or Cord Blood Transplantation (UCBT) for Thalassemia Major after Reduced Intensity Conditioning (URTH Trial Extension). Biology of Blood and Marrow Transplantation, 2016, 22, S356.	2.0	0

#	Article	IF	Citations
253	Thiamine-responsive megaloblastic anemia (TRMA) syndrome: consequences of defective high-affinity thiamine transport. , 2003, , 241-248.		0
254	Thiamine Deprivation Induces Reticulocytopenic Anemia in Slc19A2 Knockout Marrow: Evidence for Cell-Intrinsic Defect.. Blood, 2005, 106, 3604-3604.	1.4	0
255	High Prevalence of Fractures and Bone Pain in Thalassemia: The Thalassemia Clinical Research Network Experience.. Blood, 2005, 106, 2706-2706.	1.4	0
256	Hematology-Related Direct-to-Consumer Advertising: A Content Analysis and Verification of Claims from Print Media.. Blood, 2006, 108, 3346-3346.	1.4	0
257	Practical Implications of Non-Invasive MRI-Based Liver and Cardiac Iron Assessments in Children and Adults with Transfusion-Dependent Anemias.. Blood, 2007, 110, 2666-2666.	1.4	0
258	Leukocyte Apoptosis and Mitochondrial Dysfunction in Î²-Thalassemia Patients Treated with Deferasirox or Deferoxamine.. Blood, 2007, 110, 2773-2773.	1.4	0
259	Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia. Blood, 2008, 112, 3890-3890.	1.4	0
260	Systematic Analysis of Known Candidate Genes in 58 Probands with Previously Uncharacterized Congenital Sideroblastic Anemia: Evidence for Genetic Heterogeneity and Identification of Novel Mutations in ALAS2 and PUS1. Blood, 2008, 112, 484-484.	1.4	0
261	Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.. Blood, 2008, 112, 1868-1868.	1.4	0
262	Quality of Life in Adolescents and Adults with Thalassemia: A Report of the Thalassemia Longitudinal Cohort.. Blood, 2009, 114, 556-556.	1.4	0
263	A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload. Blood, 2010, 116, 2057-2057.	1.4	0
264	Retrospective Review of 524 Cases of Pediatric ITP at An Academic Medical Center: Changes In Treatment of Childhood ITP Between 2003â€“2010. Blood, 2010, 116, 2510-2510.	1.4	0
265	Derivation of Disease-Free Induced Pluripotent Stem Cells From Patients with Pearson Marrow Pancreas Syndrome. Blood, 2010, 116, 3-3.	1.4	0
266	Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia.. Blood, 2010, 116, 3681-3681.	1.4	0
267	Changes In Health Status and Quality of Life In Parental Reports of Children with Thalassemia: Year 1 Report of the Thalassemia Longitudinal Cohort Study. Blood, 2010, 116, 257-257.	1.4	0
268	Phenomenon of Pain In Thalassemia: A Prospective Analysis by the Thalassemia Clinical Research Network (TCRN). Blood, 2010, 116, 256-256.	1.4	0
269	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. Blood, 2010, 116, 2509-2509.	1.4	0
270	Disparities Between Two Common MRI Metrics of Liver Iron Concentration in Transfusional Siderosis. Blood, 2011, 118, 1088-1088.	1.4	0

#	Article	IF	Citations
271	Does Iron Overload Really Matter in Stem Cell Transplantation?. Blood, 2011, 118, 3029-3029.	1.4	0
272	Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,. Blood, 2011, 118, 3316-3316.	1.4	0
273	Liver Iron Concentration Estimates by R2* Are More Robust Than by Ferriscan During Rapid Changes in Iron Burden. Blood, 2011, 118, 5296-5296.	1.4	0
274	Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. Blood, 2011, 118, 690-690.	1.4	0
275	Intra-Patient Variability in Recombinant Activated FVII (rFVIIa) Dosing Over 3 to 8 Year Periods in Patients with Congential Hemophilia with Inhibitors Experiencing Frequent Acute Bleeding Episodes: Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry,. Blood, 2011, 118, 3314-3314.	1.4	0
276	Retrospective Review of Erythropoietin Therapy Versus Supportive Care in Newborns with Hereditary Spherocytosis (HS): Difficulties Implementing Trial Results Into Clinical Practice. Blood, 2011, 118, 2066-2066.	1.4	0
277	Treatments and Outcomes of Immune Cytopenias Following Pediatric Solid Organ Transplant. Blood, 2012, 120, 5154-5154.	1.4	0
278	High Diagnostic Utility of Second-Day Factor VIII Levels to Assess Pediatric Hemophilia A Pharmacokinetics. Blood, 2012, 120, 3368-3368.	1.4	0
279	Small Molecule Activation Of Pyruvate Kinase Normalizes Metabolic Activity In Red Cells From Patients With Pyruvate Kinase Deficiency-Associated Hemolytic Anemia. Blood, 2013, 122, 2180-2180.	1.4	0
280	Association Of Platelet Function Markers, Independent Of Platelet Count, With Bleeding Score In Patients With Immune Thrombocytopenia. Blood, 2013, 122, 3534-3534.	1.4	0
281	R2 and R2* Are Equally Effective In Evaluating Chronic Response To Iron Chelation. Blood, 2013, 122, 3437-3437.	1.4	0
282	Combined Schedule of Pneumococcal Conjugate Vaccine Followed by Pneumococcal Polysaccharide Vaccine in Patients With Sickle Cell Disease. â€¢ 779. Pediatric Research, 1997, 41, 132-132.	2.3	0
283	TIME COURSE OF EARLY ICAM-1 mRNA INDUCTION IN LUNG AND VENTRICLE FOLLOWING CARDIOPULMONARY BYPASS IN LAMBS. Critical Care Medicine, 1999, 27, 55A.	0.9	0
284	Unmet Needs in Diagnosis and Treatment of Glanzmannâ€™s Thrombasthenia (GT): Perceptions of US Hematologists and Nurses. Blood, 2014, 124, 2179-2179.	1.4	0
285	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. Blood, 2016, 128, 1008-1008.	1.4	0
286	Patient Reported Outcomes to Assess Quality of Hemophilia Care in North India - Results of a Global Partnership. Blood, 2016, 128, 3587-3587.	1.4	0
287	Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 4752-4752.	1.4	0
288	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 2175-2175.	1.4	0

#	Article	IF	Citations
289	Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study. Blood, 2021, 138, 1039-1039.	1.4	0
290	Dosing, Patient Satisfaction and Other Patient-Reported Outcomes after Switching to Rurioctocog Alfa Pegol in Athn 2: A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Coagulation Replacement Factor Products. Blood, 2020, 136, 17-18.	1.4	0